127 results
424B5
BMY
Bristol-Myers Squibb Co.
16 Feb 24
Prospectus supplement for primary offering
4:34pm
annual or special meeting of the stockholders. During the time the holders of preferred stock are entitled to elect two additional directors … by the affirmative vote of the holders of record of a majority of our shares entitled to vote, at any annual or special meeting, or, by a vote
424B2
BMY
Bristol-Myers Squibb Co.
13 Feb 24
Prospectus for primary offering
8:00am
, will be entitled to elect two directors at the next annual or special meeting of the stockholders. During the time the holders of preferred stock … , at any annual or special meeting, or, by a vote of the majority of our board of directors, at any regular or special meeting at which a quorum
DFAN14A
KRTX
Karuna Therapeutics Inc
22 Dec 23
Additional proxy materials by non-management
4:36pm
of the special meeting relating to the proposed acquisition. This communication is not a substitute for the proxy statement or any other document … . The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna Therapeutics in advance of the special meeting relating
DFAN14A
EX-99.1
behyw4 b327
22 Dec 23
Additional proxy materials by non-management
4:21pm
DFAN14A
2en5a2
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
qc0c7xl
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
8-K
pfbvz hgfi1mq
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm
424B5
7n4ksr
1 Nov 23
Prospectus supplement for primary offering
4:16pm
424B3
bd0ke hew
30 Oct 23
Prospectus supplement
8:05am
DFAN14A
mxhzq i7gp5vuc
10 Oct 23
Additional proxy materials by non-management
6:48am
DEFA14A
q73k1b
10 Apr 23
Additional proxy soliciting materials
5:12pm
8-K
EX-99.3
x17dn4m85 am35w25
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
65ydu5bghiptj1w8b
20 Apr 22
Additional proxy soliciting materials
4:30pm
424B5
y6xyz d69icd
17 Feb 22
Prospectus supplement for primary offering
4:47pm
424B3
d8k28 293y2nxqwe
15 Feb 22
Prospectus supplement
9:13am
8-K
EX-99.3
anv3yvu5fa85 agb5b
4 Feb 22
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
7:50am